Available from: (last accessed 24 September 2008) This report provides an excellent overview to the current and future market dynamics and size for drug treatments for cardiovascular-related disorders
Available from: http://www.urchpublishing. com/news/aug2007.html (last accessed 24 September 2008) • This report provides an excellent overview to the current and future market dynamics and size for drug treatments for cardiovascular-related disorders.
4
4344645978
Can the pharmaceutical industry reduce attrition rates?
This article deals with the fiscal pressures that face the pharmaceutical industry from the perspective of R&D
Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 2004;3:711-716 •• This article deals with the fiscal pressures that face the pharmaceutical industry from the perspective of R&D.
Informa UK Plc. Available from: Last accessed 2008 September
The Pharmaprojects Database, Informa UK Plc. Available from: http://www.pharmaprojects.com [Last accessed 2008 September]
6
0032562232
Induction of neoangiogenesis in ischemic myocardium by human growth factors: First clinical results of a new treatment of coronary heart disease
Schumacher B, Pecher P, Von Specht BU, Stegmann TH. Induction of neoangiogenesis in ischemic myocardium by human growth factors: first clinical results of a new treatment of coronary heart disease. Circulation 1998;97:645-650 (Pubitemid 28090957)
Effects of a potent and selective PPAR-α agonist in patients with atherogenic dyslipidemia or hypercholesterolemia: Two randomized controlled trials
DOI 10.1001/jama.297.12.1362
Nissen SE, Nicholls SJ, Wolski K, et al. Effects of a potent and selective PPAR-alpha agonist in patients with atherogenic dyslipidemia or hypercholesterolemia: two randomized controlled trials. JAMA 2007;297:1362-1373 (Pubitemid 46513237)
Available from: http://www.scienceblog.com/ community/older/1999/B/ 199901692.html (last accessed 24 September 2008)
10
12344338322
AZD7009 - a new atrial antifibrillatory compound that blocks recombinant hNav1.5 and potassium channels [abstract P2885] [plus poster]
Paulsson F, Jacobson I, Carlsson L. AZD7009 - a new atrial antifibrillatory compound that blocks recombinant hNav1.5 and potassium channels [abstract P2885] [plus poster]. Eur Heart J 2004;25 (Abstr. Suppl):479
(2004)Eur Heart J, vol.25, Issue.ABSTR. SUPPL., pp. 479
AZD7009 - a new atrial antifibrillatory compound that markedly delays atrial refractoriness and possesses low proarrhythmic activity in the anaesthetised rabbit [abstract P2939] [plus poster]
Carlsson L, Duker G, Linhardt G. AZD7009 - a new atrial antifibrillatory compound that markedly delays atrial refractoriness and possesses low proarrhythmic activity in the anaesthetised rabbit [abstract P2939] [plus poster]. Eur Heart J 2004;25 (Abstr. Suppl):492
(2004)Eur Heart J, vol.25, Issue.ABSTR. SUPPL., pp. 492